Engineering of Lurasidone hydrochloride loaded niosomes for enhancing the antipsychotic potential for nasal administration
| العنوان: | Engineering of Lurasidone hydrochloride loaded niosomes for enhancing the antipsychotic potential for nasal administration |
|---|---|
| المؤلفون: | Shailendra Bhatt, Sumit Sharma, Jai Bharti Sharma, Manish Kumar, Ravinder Verma, Deepak Kaushik |
| المصدر: | Current Nanomedicine. 13 |
| بيانات النشر: | Bentham Science Publishers Ltd., 2023. |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Biomedical Engineering, Medicine (miscellaneous), Bioengineering |
| الوصف: | Background: Drugs with high first-pass metabolism or that are susceptible to enzymatic degradation can be administered through the nasal route to avoid their degradation. Lurasidone exhibits less toxicity and side effects as compared to its sister drugs like risperidone, ziprasidone, clozapine, etc. Objectives: The present study aimed to develop Lurasidone loaded niosomes for nasal delivery. Methods: Lurasidone niosomes were developed by adapting the ether injection method and optimized using a central composite design. In vitro and in vivo studies were conducted using optimized formulation. Results: The findings showed that the optimized formulation exhibited a particle size of 159.02 ± 0.58 nm and an entrapment efficiency of 91.6 ± 1.6 %. The findings from the nasal histopathological analysis revealed that the optimized formulation was non-irritant and non-toxic for nasal mucosa. The findings from in vitro studies revealed 94.61 ± 0.27 % of drug release from optimized formulation F7 throughout 24 hrs. The findings of in vivo (Albino Wistar rats) studies demonstrated that various pharmacokinetic parameters (Cmax, Tmax, AUC(0-24), T1/2, Vd and Cl) and pharmcodynamic parameters (conditioned avoidance response, biochemical estimation using oxidative markers such as superoxide dismutase, malondialdehyde and glutathione) were significantly improved compared to marketed tablets (Lurasid® 40 mg) and pure drug suspension. Optimized formulation F-7 exhibited 4.9 times more bioavailability than that of pure drug suspension following intranasal administration. Conclusion: These findings indicate that nasal niosomal formulation of Lurasidone HCl is a promising nanoplatform for enhancing the overall performance of Lurasidone. These results could open new avenues into the future of nanomedicine. |
| تدمد: | 2468-1873 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::2ca1ce3c417b0f63bd982709637d5882 https://doi.org/10.2174/2468187313666230117163425 |
| رقم الأكسشن: | edsair.doi...........2ca1ce3c417b0f63bd982709637d5882 |
| قاعدة البيانات: | OpenAIRE |
كن أول من يترك تعليقا!